发明名称 |
Antipsychotic treatment based on SNP genotype |
摘要 |
The present invention relates to the prediction of antipsychotic treatment efficacy based on a patient's genotype at one or more single nucleotide polymorphism (SNP) loci and to the treatment of a patient based on such prediction. |
申请公布号 |
US9328387(B2) |
申请公布日期 |
2016.05.03 |
申请号 |
US200812675598 |
申请日期 |
2008.09.10 |
申请人 |
Vanda Pharmaceuticals, Inc. |
发明人 |
Lavedan Christian;Volpi Simona;Licamele Louis;Polymeropoulos Mihael H. |
分类号 |
C12Q1/68;C12P19/34 |
主分类号 |
C12Q1/68 |
代理机构 |
Hoffman Warnick LLC |
代理人 |
Hoffman Warnick LLC |
主权项 |
1. A method of treating a human individual with at least one psychotic symptom comprising:
a) determining the individual's genotype at the single nucleotide polymorphism (SNP) locus rs4528226; and b) administering to the individual a first effective amount of between about 2 mg/day and about 24 mg/day of iloperidone, a pharmaceutically-acceptable salt thereof, a metabolite thereof, or a pharmaceutically-acceptable salt of a metabolite thereof in the case that the individual's genotype at rs4528226 is GT; or administering to the individual a second effective amount of iloperidone, a pharmaceutically-acceptable salt thereof, a metabolite thereof, or a pharmaceutically-acceptable salt of a metabolite thereof in the case that the individual's genotype at rs4528226 is not GT, wherein the second effective amount is between about 24 mg/day and about 50 mg/day and greater than the amount administered to an individual that has a GT genotype at the rs4528226 locus. |
地址 |
Washington DC US |